Trial Profile
A Phase I, single ascending dose (SAD) study of VYR-006
Status:
Planning
Phase of Trial:
Phase I
Latest Information Update: 10 Dec 2018
Price :
$35
*
At a glance
- Drugs Fanotaprim (Primary)
- Indications Toxoplasmosis
- Focus Adverse reactions
- 10 Dec 2018 New trial record
- 15 Nov 2018 According to a Vyera Pharmaceuticals media release, the U.S. FDA has approved the investigational new drug application for VYR-006 on November 6, 2018.